Optical Coherence Tomography Predictors of Favorable Functional Response in Naïve Diabetic Macular Edema Eyes Treated with Dexamethasone Implants as a First-Line Agent
Table 2
Functional and morphological biomarkers before and after treatment.
Variables
Baseline
3 months
value Baseline vs. 3 Mo
6 months
value Baseline vs. 6 Mo
12 months
value Baseline vs. 12 Mo
BCVA ETDRS letters
51.6 ± 17.1
58.9 ± 16.5
0.01
57.6 ± 17.3
0.03
56.9 ± 17.5
0.03
CMT (µm)
434.4 ± 155.6
284.7 ± 108.7
<0.001
284.7 ± 108.7
0.001
336.8 ± 151.1
0.001
SRD presence, n (%) Height (µm)
18 (46.2) 32.6 ± 52.7
2 (5.1) 6.5 ± 22.8
<0.001 <0.001
3 (7.7) 13.5 ± 32.1
<0.001 0.001
3 (7.7) 14.1 ± 28.1
<0.001 0.001
HRS (n)
25.5 ± 13.8
16.2 ± 15.2
0.02
18.7 ± 12.6
0.03
25.7 ± 12.6
0.03
Cysts size (µm)
2216.1 ± 1230.9
631.1 ± 763.1
0.001
1384.4 ± 952.9
0.001
1384.4 ± 952.9
0.01
CT Subfoveal (µm) Nasal (µm) Temporal (µm)
178.6 ± 65.9 155.8 ± 31.8 163.4 ± 39.7
178.6 ± 65.9 155.8 ± 31.8 163.4 ± 39.7
0.32 0.44 0.32
178.6 ± 65.9 155.8 ± 31.8 163.4 ± 39.7
0.41 0.15 0.31
178.6 ± 65.9 155.8 ± 31.8 163.4 ± 39.7
0.19 0.28 0.33
DRIL presence, n (%)
8 (20.5)
7 (17.9)
0.77
7 (17.9)
0.77
7 (17.9)
0.77
EZ integrity, n (%)
23 (58.9)
22 (56.4)
0.82
22 (56.4)
0.82
22 (56.4)
0.82
Vitreomacular interface PVD, n (%) VMA, n (%) VMT, n (%)
7 (17.9) 11 (28.2) 4 (10.3)
7 (17.9) 11 (28.2) 3 (7.7)
— — 0.69
8 (20.5) 11 (28.2) 3 (7.7)
0.77 — .69
8 (20.5) 11 (28.2) 3 (7.7)
0.77 — .69
BCVA: best-corrected visual acuity; ETDRS: Early Treatment Diabetic Retinopathy study; CMT: central macular thickness; SRD: serous retinal detachment; HRS: hyper-reflective spots; CT: choroidal thickness; DRIL: disorganization of the inner retinal layers; EZ: ellipsoid zone; PVD: posterior vitreous detachment; VMA: vitreomacular adhesion; VMT: vitreomacular traction. Values in bold indicate value < .05.
